106. Puente-Maestu L, García de Pedro J, Benedetti PA, et al. Reference values in adults. In: Palange P, Laveneziana P, Neder JA, et al., eds. Clinical Exercise Testing (ERS Monograph). Sheffield, European Respiraotry Society, 2018 pp. 82–106. 107. Burghard M, Hulzebos EHJ, Olin JT, et al. Exercise testing in children with respiratory diseases. In: Palange P, Laveneziana P, Neder JA, et al., eds. Clinical Exercise Testing (ERS Monograph). Sheffield, European Respiraotry Society, 2018 pp. 196–215. 108. Killian KJ, Summers E, Jones NL, et al. Dyspnea and leg effort during incremental cycle ergometry. Am Rev Respir Dis 1992 145: 1339–1345. 109. McEvoy JD, Jones NL. Arterialized capillary blood gases in exercise studies. Med Sci Sports 1975 7: 312–315. 110. Hoffmann U, Essfeld D, Stegemann J. Comparison of arterial, end-tidal and transcutaneous PCO2 during moderate exercise and external CO2 loading in humans. Eur J Appl Physiol 1990 61: 1–4. 111. Stege G, van den Elshout FJJ, Heijdra YF, et al. Accuracy of transcutaneous carbon dioxide tension measurements during cardiopulmonary exercise testing. Respir Int Rev Thorac Dis 2009 78: 147–153. 112. Bhatt DV, Kocheril AG. Submaximal cardiopulmonary exercise testing for the evaluation of unexplained dyspnea. South Med J 2014 107: 144–149. 113. Singh SJ, Harvey-Dunstan TC. Walking for the assessment of patients with COPD. In: Palange P, Laveneziana P, Neder JA, et al., eds. Clinical Exercise Testing (ERS Monograph). Sheffield, European Respiraotry Society, 2018 pp. 175–195. 114. Malaguti C, Nery LE, Dal Corso S, et al. Alternative strategies for exercise critical power estimation in patients with COPD. Eur J Appl Physiol 2006 96: 59–65. 115. Degani-Costa LH, O’Donnell DE, Webb K, et al. A simplified approach to select exercise endurance intensity for interventional studies in COPD. COPD 2018 (DOI: 10.1080/15412555.2018.1428944). 116. van der Vaart H, Murgatroyd SR, Rossiter HB, et al. Selecting constant work rates for endurance testing in COPD: the role of the power-duration relationship. COPD 2014 11: 267–276. 117. Calzetta L, Rogliani P, Matera MG, et al. A systematic review with meta-analysis of dual bronchodilation with LAMA/LABA for the treatment of stable COPD. Chest 2016 149: 1181–1196. 118. Ferreira EM, Ota-Arakaki JS, Barbosa PB, et al. Signal-morphology impedance cardiography during incremental cardiopulmonary exercise testing in pulmonary arterial hypertension. Clin Physiol Funct Imaging 2012 32: 343–352. 119. Agostoni P, Vignati C, Gentile P, et al. Reference values for peak exercise cardiac output in healthy individuals. Chest 2017 151: 1329–1337. Disclosures: J.A. Neder has received research funding via Queen’s University from Boehringer Ingelheim and has served on speakers’ bureaus, consultation panels and advisory boards for AstraZeneca, Boehringer Ingelheim and Chiesi Pharmaceutici. P. Laveneziana reports receiving personal fees from the following, outside the submitted work: Novartis France and Boehringer France. https://doi.org/10.1183/2312508X.10015318 xxv